Latest Insider Transactions at Kiniksa Pharmaceuticals, Ltd. (KNSA)
This section provides a real-time view of insider transactions for Kiniksa Pharmaceuticals, Ltd. (KNSA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Kiniksa Pharmaceuticals, Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Kiniksa Pharmaceuticals, Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 06
2024
|
Richard S Levy |
BUY
Exercise of conversion of derivative security
|
Direct |
4,373
+25.32%
|
-
|
|
Jun 06
2024
|
G Bradley Cole |
BUY
Exercise of conversion of derivative security
|
Direct |
4,373
+31.81%
|
-
|
|
Jun 06
2024
|
Barry D Quart |
BUY
Exercise of conversion of derivative security
|
Direct |
4,373
+31.81%
|
-
|
|
Jun 06
2024
|
Kimberly J Popovits |
BUY
Exercise of conversion of derivative security
|
Direct |
4,373
+31.81%
|
-
|
|
Jun 06
2024
|
Tracey L Mc Cain |
BUY
Exercise of conversion of derivative security
|
Direct |
4,373
+31.81%
|
-
|
|
Jun 06
2024
|
Thomas Malley |
BUY
Exercise of conversion of derivative security
|
Direct |
4,373
+31.81%
|
-
|
|
Jun 05
2024
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
12,692
+2.55%
|
-
|
|
May 03
2024
|
Richard S Levy |
BUY
Exercise of conversion of derivative security
|
Direct |
747
+8.06%
|
-
|
|
Apr 26
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
509
-2.58%
|
$8,653
$17.88 P/Share
|
|
Apr 26
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
991
+4.78%
|
-
|
|
Apr 08
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
791
-4.04%
|
$13,447
$17.9 P/Share
|
|
Apr 08
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,694
+12.1%
|
-
|
|
Apr 08
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
733
-1.51%
|
$12,461
$17.9 P/Share
|
|
Apr 08
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,497
+4.89%
|
-
|
|
Apr 08
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,075
-6.07%
|
$69,275
$17.9 P/Share
|
|
Apr 08
2024
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,992
+12.96%
|
-
|
|
Apr 08
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
801
-0.63%
|
$13,617
$17.9 P/Share
|
|
Apr 08
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,726
+2.1%
|
-
|
|
Apr 08
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,666
-7.25%
|
$28,322
$17.9 P/Share
|
|
Apr 08
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,932
+14.6%
|
-
|
|
Apr 08
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,353
-7.67%
|
$23,001
$17.9 P/Share
|
|
Apr 08
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,477
+12.32%
|
-
|
|
Apr 01
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
514
-2.96%
|
$9,766
$19.7 P/Share
|
|
Apr 01
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,750
+9.15%
|
-
|
|
Apr 01
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
880
-5.49%
|
$16,720
$19.7 P/Share
|
|
Apr 01
2024
|
Ross Moat CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,612
+9.14%
|
-
|
|
Apr 01
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,084
-5.38%
|
$20,596
$19.7 P/Share
|
|
Apr 01
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,558
+11.27%
|
-
|
|
Apr 01
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,903
-3.23%
|
$36,157
$19.7 P/Share
|
|
Apr 01
2024
|
Sanj K Patel CHAIRMAN & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,482
+9.9%
|
-
|
|
Apr 01
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
521
-0.42%
|
$9,899
$19.7 P/Share
|
|
Apr 01
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,773
+1.4%
|
-
|
|
Apr 01
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
477
-1.03%
|
$9,063
$19.7 P/Share
|
|
Apr 01
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,624
+3.37%
|
-
|
|
Mar 07
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Indirect |
65,012
-100.0%
|
$1,365,252
$21.02 P/Share
|
|
Mar 06
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Indirect |
5,582
-7.91%
|
$117,222
$21.0 P/Share
|
|
Mar 04
2024
|
Sanj K Patel CHAIRMAN & CEO |
SELL
Open market or private sale
|
Indirect |
12,742
-7.9%
|
$267,582
$21.66 P/Share
|
|
Mar 01
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
1,189
-0.96%
|
$26,158
$22.03 P/Share
|
|
Mar 01
2024
|
Eben Tessari CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
656
+0.53%
|
$656
$1.59 P/Share
|
|
Mar 01
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
18,844
-29.57%
|
$395,724
$21.77 P/Share
|
|
Mar 01
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,844
+23.1%
|
$18,844
$1.86 P/Share
|
|
Mar 01
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
9,659
-35.45%
|
$202,839
$21.45 P/Share
|
|
Mar 01
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,659
+16.19%
|
$106,249
$11.36 P/Share
|
|
Feb 28
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
5,126
-22.57%
|
$107,646
$21.79 P/Share
|
|
Feb 28
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,126
+18.41%
|
$41,008
$8.83 P/Share
|
|
Feb 27
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,156
-18.45%
|
$213,276
$21.03 P/Share
|
|
Feb 27
2024
|
John F. Paolini CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,156
+15.58%
|
$10,156
$1.86 P/Share
|
|
Jan 15
2024
|
Michael R Megna CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
583
+3.21%
|
$6,996
$12.35 P/Share
|
|
Jan 03
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
12,000
-43.43%
|
$240,000
$20.0 P/Share
|
|
Jan 03
2024
|
Mark Ragosa CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+30.28%
|
$96,000
$8.83 P/Share
|